Voyager Therapeutics, Inc. (VYGR) — Analyst outlook / Analyst consensus target is. Based on 21 analyst ratings, the consensus is bullish — 17 Buy, 4 Hold.
The consensus price target is $14.40 (low: $8.00, high: $18.00), representing an upside of 263.4% from the current price $3.96.
Analysts estimate Earnings Per Share (EPS) of $-0.92 and revenue of $0.09B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.13 vs est $-0.92 (missed -22.3%). 2025: actual $-2.04 vs est $-2.09 (beat +2.4%). Analyst accuracy: 90%.
VYGR Stock — 12-Month Price Forecast
$14.40
▲ +263.36% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for Voyager Therapeutics, Inc., the average price target is $14.40, with a high forecast of $18.00, and a low forecast of $8.00.
The average price target represents a +263.36% change from the last price of $3.96.
Highest Price Target
$18.00
Average Price Target
$14.40
Lowest Price Target
$8.00
VYGR Analyst Ratings
Buy
Based on 21 analysts giving stock ratings to Voyager Therapeutics, Inc. in the past 3 months
EPS Estimates — VYGR
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.13
vs Est –$0.92
▼ 18.2% off
2025
Actual –$2.04
vs Est –$2.09
▲ 2.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — VYGR
88%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.080B
vs Est $0.090B
▼ 12.9% off
2025
Actual $0.040B
vs Est $0.036B
▲ 12.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
